方盛製藥(603998.SH):目前公司日常經營管理和業務狀況一切正常
格隆匯8月11日丨方盛製藥(603998.SH)近期在接待機構投資者調研時表示,本次醫藥行業反腐,有利於創造更加公平的競爭環境、提高醫藥企業的公眾形象和信譽。在公平的市場環境下,企業將會增加對研發的投入,提高產品質量和創新能力。企業也將更加重視合規性,建立更為完善的內部控制和合規體系。
公司設立審計監察部門,加強對關鍵崗位人員的監督檢查,對關鍵崗位人員的對外兼職、對外投資、廉潔守法等方面行為進行規範,始終嚴守合規底線,以高標準、嚴要求,全方位打造合規文化,促進公司健康可持續發展。目前公司日常經營管理和業務狀況一切正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.